{"id":"NCT03022097","sponsor":"AstraZeneca","briefTitle":"Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients","officialTitle":"A 24-week Treatment, Randomised, Parallel-group, Double Blinded, Double-Dummy, Multicenter Study to Assess the Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Compared With Individual Components and Placebo and Aclidinium Bromide Compared With Placebo When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-02-02","primaryCompletion":"2022-04-14","completion":"2022-04-14","firstPosted":"2017-01-16","resultsPosted":"2025-03-26","lastUpdate":"2025-03-26"},"enrollment":1625,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["COPD"],"interventions":[{"type":"DRUG","name":"Aclidinium bromide/formoterol Fixed-Dose Combination","otherNames":[]},{"type":"DRUG","name":"Aclidinium bromide","otherNames":[]},{"type":"DRUG","name":"Formoterol Fumarate","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Experimental 1","type":"EXPERIMENTAL"},{"label":"Experimental 2","type":"EXPERIMENTAL"},{"label":"Comparator","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a multiple dose, randomised, parallel, double blind, double dummy, multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide/Formoterol fumarate compared with individual components and placebo and Aclidinium bromide compared with Placebo when administered to patients with stable Chronic Obstructive Pulmonary Disease (COPD).","primaryOutcome":{"measure":"Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1)","timeFrame":"Week 24, 1-hour morning post-dose","effectByArm":[{"arm":"AB/FF 400/12 μg","deltaMin":0.248,"sd":0.013},{"arm":"AB 400 μg","deltaMin":0.156,"sd":0.013},{"arm":"FF 12 μg","deltaMin":0.138,"sd":0.013},{"arm":"Placebo","deltaMin":-0.05,"sd":0.013}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":25},"locations":{"siteCount":74,"countries":["China","India","Philippines","Taiwan","Vietnam"]},"refs":{"pmids":[],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D6570C00002&amp;attachmentIdentifier=0136b8b2-5200-4274-bc73-a2b8e01690db&amp;fileName=d6570c00002-CSR-synopsis.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":263},"commonTop":["Chronic obstructive pulmonary disease","Upper respiratory tract infection"]}}